AG + leucovorin + fluorouracil + oxaliplatin + serplulimab + bevacizumab

A combination therapy regimen consisting of AG, leucovorin, fluorouracil (5-FU), oxaliplatin, serplulimab, and bevacizumab. This regimen likely combines traditional chemotherapy agents (fluorouracil, leucovorin, oxaliplatin) with targeted therapy (bevacizumab) and immunotherapy (serplulimab). Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, while leucovorin enhances its cytotoxic effects. Oxaliplatin is a platinum-based agent that forms DNA adducts. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis. Serplulimab is likely an immune checkpoint inhibitor targeting PD-1. The AG component is not clearly identified in the available information.